Genes differentially expressed within peripheral blood mononuclear cells, comparing pretreatment baseline vs day 7 of study
| Gene . | Visit fold change . | Adjusted P . | Response fold change . | Adjusted P . |
|---|---|---|---|---|
| RPS6KA5 | 0.35 | .02 | 1.67 | <.001 |
| CCR3 | 0.57 | .02 | 2.39 | <.001 |
| MEF2C | 0.68 | .02 | 2.95 | .01 |
| ROCK2 | 0.53 | .02 | 1.77 | .02 |
| TLR3 | 0.62 | .02 | 1.92 | .03 |
| MAP2K4 | 0.55 | .00 | 1.40 | .03 |
| CYSLTR2 | 0.51 | .04 | 1.86 | .03 |
| OAS2 | 0.63 | .04 | 2.23 | .03 |
| STAT2 | 0.37 | .04 | 1.32 | .03 |
| STAT1 | 0.56 | .02 | 1.69 | .04 |
| MYC | 0.48 | .03 | 1.45 | .06 |
| CCR2 | 0.91 | .04 | 2.72 | .08 |
| GNB1 | 0.24 | .02 | 0.57 | .11 |
| LTB | 0.67 | .01 | 1.33 | .11 |
| CXCL10 | 1.32 | .03 | 3.17 | .12 |
| PRKCA | 0.41 | .02 | 0.90 | .12 |
| LTA | 0.40 | .03 | 0.92 | .14 |
| CEBPB | −0.37 | .04 | −0.86 | .17 |
| CRP | −0.50 | .04 | −1.00 | .23 |
| TLR5 | 0.60 | .02 | 1.00 | .24 |
| CCL16 | −0.67 | .02 | −1.00 | .29 |
| TRAF2 | 0.37 | .03 | 0.46 | .42 |
| CD4 | 0.48 | .03 | 0.46 | .52 |
| IL6 | 1.49 | .02 | 1.13 | .59 |
| OXER1 | 0.39 | .02 | −0.28 | .61 |
| Gene . | Visit fold change . | Adjusted P . | Response fold change . | Adjusted P . |
|---|---|---|---|---|
| RPS6KA5 | 0.35 | .02 | 1.67 | <.001 |
| CCR3 | 0.57 | .02 | 2.39 | <.001 |
| MEF2C | 0.68 | .02 | 2.95 | .01 |
| ROCK2 | 0.53 | .02 | 1.77 | .02 |
| TLR3 | 0.62 | .02 | 1.92 | .03 |
| MAP2K4 | 0.55 | .00 | 1.40 | .03 |
| CYSLTR2 | 0.51 | .04 | 1.86 | .03 |
| OAS2 | 0.63 | .04 | 2.23 | .03 |
| STAT2 | 0.37 | .04 | 1.32 | .03 |
| STAT1 | 0.56 | .02 | 1.69 | .04 |
| MYC | 0.48 | .03 | 1.45 | .06 |
| CCR2 | 0.91 | .04 | 2.72 | .08 |
| GNB1 | 0.24 | .02 | 0.57 | .11 |
| LTB | 0.67 | .01 | 1.33 | .11 |
| CXCL10 | 1.32 | .03 | 3.17 | .12 |
| PRKCA | 0.41 | .02 | 0.90 | .12 |
| LTA | 0.40 | .03 | 0.92 | .14 |
| CEBPB | −0.37 | .04 | −0.86 | .17 |
| CRP | −0.50 | .04 | −1.00 | .23 |
| TLR5 | 0.60 | .02 | 1.00 | .24 |
| CCL16 | −0.67 | .02 | −1.00 | .29 |
| TRAF2 | 0.37 | .03 | 0.46 | .42 |
| CD4 | 0.48 | .03 | 0.46 | .52 |
| IL6 | 1.49 | .02 | 1.13 | .59 |
| OXER1 | 0.39 | .02 | −0.28 | .61 |
Visit fold change indicates comparison between baseline and day 7. Response fold change indicates comparison between patients with CR/PR vs NR at day 28. Boldface indicates set of genes that significantly increased from baseline to day 7 in patients with a CR or PR at day 28.